San Sheng Guo Jian: Both the 608 project and the 613 project have submitted new drug marketing applications to the CDE and have been accepted.

An investor asked Sancken Genkis on the interactive platform: I noticed that the company is focusing on the field of self-immunity, focusing on its own immune diseases, with pipeline products such as IL-17A monoclonal antibody, IL-5 monoclonal antibody entering Phase III or NDA stage. Will it be gradually commercialized in the second half of 2025? Sancken Genkis replied that both the 608 project and the 613 project have already submitted new drug marketing applications to the CDE and have been accepted. However, since the new drug marketing application still needs to undergo evaluation, on-site inspections of clinical drug trials, on-site inspections of drug production, and approval procedures, there is uncertainty regarding whether the product can successfully enter the market and the time of market entry. The company will fulfill its disclosure obligations in a timely manner regarding the progress of subsequent developments according to relevant regulations.